Sinco Pharmaceuticals Sets 2026 AGM to Approve Dividend, Board Mandates and New Share-Issuance Authority

Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ) just unveiled an announcement.

Sinco Pharmaceuticals Holdings Limited has called its annual general meeting for 15 May 2026 in Chengdu, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the related directors’ and auditor’s reports. Investors will also vote on the re-election of three independent non-executive directors, the re-appointment of Rongcheng (Hong Kong) CPA Limited as auditor, the declaration of a final dividend of HK$3.4 million, and a general mandate allowing the board to issue additional shares under defined limits, which together shape the company’s governance, capital flexibility and shareholder returns for the coming year.

These resolutions, if approved, will affirm the current board and oversight structure while providing management with continued authority to raise equity capital through new share issuances outside of rights issues and employee schemes. The proposed dividend signals ongoing profitability and a continued commitment to distributing cash to shareholders, although the share-issuance mandate could dilute existing holdings if exercised, balancing income with potential future growth financing needs.

More about Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates in the pharmaceutical sector. The group focuses on developing and supplying pharmaceutical products and related healthcare offerings to the Chinese market, positioning itself within the broader healthcare and life sciences industry.

Average Trading Volume: 240,636

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$345.6M

Find detailed analytics on 6833 stock on TipRanks’ Stock Analysis page.